Microsoft: Analysts Anticipate Q4 Earnings Per Share Of $2.29

Microsoft (NASDAQ: MSFT) will be reporting its fiscal fourth quarter financials today after markets close. Analysts have a consensus $344 12-month price target on the company, via a total of 52 analysts, with 19 analysts having strong buy ratings. 30 analysts meanwhile have buy ratings and three analysts have hold ratings. The street high sits at a $426 price target, and the lowest target sits at $252.

24 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 24 analysts is $52.39 billion; this number is flat year to date now. The highest revenue estimate is $52.9 billion, while the lowest is $51.74 billion.

Onto EBITDA estimates, there are currently only six analysts who have fourth-quarter EBITDA estimates. The mean is currently $25.1 billion, with this number having been revised downwards from $25.4 billion at the start of the year. Street high is a $25.34 billion EBITDA estimate and the lowest is $24.88 billion.

Analysts estimate that quarterly earnings per share will come in at $2.29, with this number being revised steadily down since the start of the year. Street high is $2.35, and the lowest estimate is $2.24 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is This the Most Overlooked Critical Mineral? (+1000% Move) | Guy Bourassa – Scandium Canada

Is Gold Entering a New 15-Year Cycle? | Rob Husband

A 100,000 Ounce Per Year Gold Plan in Utah | Scott Trebilcock — Revival Gold

Recommended

Silver47 Launches 7,000-Meter Hughes Drill Program In Nevada

Advanced Gold Acquires Nevada Property With Historic Production At 1,611 g/t Silver

Related News

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

Canopy Growth: Canaccord Reduces Target To $6, Anticipates Further Cost Cutting

Canopy Growth (TSX: WEED) is expected to report its fiscal fourth-quarter financial results tomorrow morning....

Thursday, May 26, 2022, 04:32:00 PM

Canopy Growth: Analysts Expect Q2 Revenues Of $142.5 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Thursday, November 4, 2021, 03:16:00 PM

Aurora Cannabis: Stifel Lowers Rating To Hold, Price Target Falls To $10.50 From $16

Yesterday, Aurora Cannabis (TSX: ACB) (NYSE: ACB) provided a business update. The firm announced that...

Wednesday, September 9, 2020, 01:47:00 PM

K92 Mining Sees Analysts Reiterate Ratings Following Drill Results

Last week, K92 Mining Inc. (TSX: KNT) reported their Judd Vein System drill results, which...

Sunday, September 5, 2021, 04:50:00 PM